Last $91.00 USD
Change Today +0.09 / 0.10%
Volume 3.6M
COV On Other Exchanges
New York
As of 8:04 PM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

covidien plc (COV) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/16/14 - $92.68
52 Week Low
07/11/13 - $58.71
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for COVIDIEN PLC (COV)

covidien plc (COV) Related Businessweek News

View More BusinessWeek News

covidien plc (COV) Details

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. The company’s Medical Devices segment develops, manufactures, and sells endomechanical instruments, such as laparoscopic instruments, surgical staplers, and interventional lung solutions; energy devices, including vessel sealing, electrosurgical, and ablation products and related capital equipment; and soft tissue repair products comprising sutures, mesh, biosurgery products, and hernia mechanical devices. This segment also offers vascular products, such as compression, dialysis, venous insufficiency, thrombectomy, neurovascular, and peripheral vascular products; oximetry and monitoring products, including sensors, monitors, and temperature management products; and airway and ventilation products comprising airway, ventilator, breathing systems, and inhalation therapy products. Its products are used primarily by hospitals and ambulatory care centers, as well as alternate site healthcare providers, such as physician offices. The company’s Medical Supplies segment develops, manufactures, and distributes nursing care products comprising incontinence, wound care, enteral feeding, urology, and suction products; medical surgical products, such as operating room supply products related accessories, electrodes, thermometry, and chart paper product lines; SharpSafety products, including needles, syringes, and sharps disposal products; and original equipment manufacturer products. Its products are used primarily in hospitals, surgi-centers, and alternate care facilities, such as homecare and long-term care facilities. The company markets its products through direct sales force and third-party distributors. Covidien plc is based in Dublin, Ireland.

38,500 Employees
Last Reported Date: 11/21/13

covidien plc (COV) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.2M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $783.5K
Senior Vice President and Group President of ...
Total Annual Compensation: $556.6K
Senior Vice President and Group President of ...
Total Annual Compensation: $556.6K
Senior Vice President and General Counsel
Total Annual Compensation: $580.9K
Compensation as of Fiscal Year 2013.

covidien plc (COV) Key Developments

Covidien Announces European Launch of Pipeline(TM) Flex Embolization Device

Further strengthening its broad line of neurovascular products to treat unruptured brain aneurysms, Covidien plc announced the European launch of its Pipeline(TM) Flex embolization device at the annual Live Interventional Neuroradiology & Neurosurgery Course (LINNC), held in Paris June 23-25. This next-generation flow diversion device received CE Mark earlier 2014. Covidien's Pipeline(TM) Flex embolization device is the next advancement in flow diversion in Europe. Designed to divert blood flow away from an aneurysm, the Pipeline Flex device features a braided cylindrical mesh tube that is implanted across the base or neck of the aneurysm. The device cuts off blood flow to the aneurysm, reconstructing the diseased section of the parent vessel. The device is repositionable and designed for even more accuracy and controlled placement. Among other features, it includes an instant braid release system that makes it even easier to place. In Europe, the Pipeline Flex device is intended for the endovascular embolization of cerebral aneurysms. The Pipeline Flex device is not currently approved for use in the U.S.

Covidien plc, Medtronic, Inc. - M&A Call

To discuss agreement under which Medtronic, Inc. has agreed to acquire Covidien plc in a cash-and-stock transaction

Covidien plc Receives FDA Approval of its Apollo(TM) Onyx(TM) Delivery Micro Catheter

Covidien plc announced U.S. Food and Drug Administration (FDA) approval of its Apollo(TM) Onyx(TM) delivery micro catheter - the first detachable tip micro catheter available in the U.S. The new micro catheter is designed to mitigate the technical challenges of catheter retrieval during Onyx(TM) LES embolizations of brain arteriovenous malformations (bAVMs). FDA approves Covidien's Apollo(TM) Onyx(TM) delivery micro catheter - the first detachable tip micro catheter available in the U.S. A bAVM occurs when a tangle of blood vessels in the brain or on its surface bypasses normal brain tissue and directly diverts blood from the arteries to the veins. Normally, arteries carry blood containing oxygen from the heart to the brain, and veins carry blood with less oxygen away from the brain and back to the heart. According to the American Heart Association, bAVMs occur in approximately one in 200--500 people and are more common in males than in females. The Apollo Onyx micro catheter enables physicians to choose the best catheter position for each procedure. It provides optimal navigability through complex distal anatomy as well as a proprietary detachable tip designed for easier catheter retrieval in challenging environments. The Apollo Onyx micro catheter will be showcased at the Society of NeuroInterventional Surgery's (SNIS) 11(th) annual meeting to be held July 28 in Colorado Springs, Colo.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COV:US $91.00 USD +0.09

COV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $216.52 USD -0.76
Baxter International Inc $76.75 USD +0.93
Becton Dickinson and Co $118.87 USD -0.60
Kimberly-Clark Corp $112.81 USD -0.25
Stryker Corp $83.68 USD -0.30
View Industry Companies

Industry Analysis


Industry Average

Valuation COV Industry Range
Price/Earnings 26.1x
Price/Sales 4.0x
Price/Book 4.3x
Price/Cash Flow 25.5x
TEV/Sales 3.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COVIDIEN PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at